BioNTech SE

BioNTech SE engages in the development of novel medicines at the intersection of immunology and synthetic biology. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioNTech reports robust 2022 earnings, eyes growth in oncology and infectious diseases

BioNTech's strong financial performance in 2022 sets the stage for continued growth in 2023, with a focus on expanding its vaccine portfolio, advancing oncology programs, and navigating the evolving landscape of COVID-19. The company's strategic priorities align with market demands for infectious disease and oncology solutions, positioning BioNTech for future success and profitability.

BioNTech posts robust Q1 results, eyes growth in vaccines and oncology

BioNTech's Q1 2023 performance reflects strong financial results and promising developments in its vaccine and oncology programs.
While facing challenges such as seasonal trends and data constraints, the company is strategically positioned to leverage opportunities in commercial planning and therapeutic advancements.
With a focus on synergistic partnerships and innovative technologies, BioNTech aims to maintain its competitive edge in the biopharmaceutical industry.
The company's commitment to enhancing existing platforms and exploring new growth avenues underscores its resilience and adaptability in a dynamic market environment.

BioNTech reports mixed Q2 results, focuses on innovation and growth

BioNTech's Q2 2023 performance reflects a mix of strong revenue generation and financial challenges, emphasizing the importance of strategic focus.
The company's strengths lie in its innovative collaborations, pipeline advancements, and preparedness for market demands, despite facing financial losses.
Navigating challenges in financial sustainability, market competition, and stakeholder communication will be crucial for BioNTech's future growth and success.

BioNTech adjusts revenue guidance amidst vaccine demand challenges

BioNTech's Q3 2023 performance reflected revenue challenges from lower COVID-19 vaccine demand and write-downs, prompting revised revenue guidance.
Despite challenges, the company showcased strengths in vaccine development, oncology advancements, and strategic cost management initiatives.
Opportunities lie in shared R&D expenses, long-term growth prospects from combination vaccines, and maintaining financial strength during market transition.

BioNTech reports strong Q4 earnings, eyes diversified product expansion

BioNTech is strategically investing in expanding its product portfolio while navigating uncertainties in COVID-19 vaccine revenues. The company aims to transform into a multiproduct company by 2030, focusing on oncology and infectious diseases.

BioNTech advances oncology pipeline, eyes growth amid financial challenges

BioNTech is making significant strides in its oncology pipeline, aiming for multiple product launches by 2026 and focusing on cancer vaccines and mRNA treatments.
While facing financial losses and short-term profitability challenges, the company remains optimistic about its growth trajectory and revenue potential.
Strategic investments in technology platforms, commercial readiness, and partnerships position BioNTech for sustainable growth and value enhancement.
Balancing cost control, revenue generation, and clinical execution will be crucial for BioNTech to capitalize on opportunities and navigate challenges effectively.

BioNTech reports Q2 progress in oncology pipeline amid financial challenges

BioNTech's Q2 2024 earnings call highlighted progress in oncology and COVID-19 vaccines, with total revenues of EUR 129 million but a net loss of EUR 808 million. The company remains focused on advancing innovative therapies and expanding its global manufacturing capabilities.

BioNTech reports robust Q3 earnings, focuses on oncology pipeline

BioNTech's Q3 2024 performance was strong, driven by COVID-19 vaccines and oncology trials.
While facing revenue challenges in certain regions, the company remains focused on growth.
Opportunities lie in advancing oncology pipeline and demonstrating product potential.
Maintaining a strong cash position provides flexibility for future investments.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

BioNTech: The EU Deal Is Fantastic But Watch The Manufacturing Targets

AstraZeneca

Pfizer

In this week's coronavirus (COVID-19) vaccine news, the UK has reached the 60mln milestone of administered doses.  That includes 22mln people having received both shots required to complete the immunisation course.

Coronavirus vaccines: UK hits 60mln doses milestone as new study proves AstraZeneca, Pfizer/BioNTech jabs work against Indian variant

The Best News and Worst News from BioNTech's Q1 Results

Up 300% since last May, can BioNTech further unlock value for shareholders?

Is BioNTech a Buy?

Pfizer Inc (NYSE: PFE) and the Indian government are at loggerheads over a demand by the company for legal protection from any claims linked to the use of its COVID-19 vaccine, said Reuters citing two sources. What Happened: India has not given any manufacturer of a COVID-19 vaccine indemnity against the costs of compensation for any severe side effects.

Pfizer Hits Deadlock With India Over Vaccine Indemnity Issue: Reuters

Pfizer (PFE)/BioNTech (BNTX) have a total supply order for 2.4 billion doses of its COVID-19 vaccine, Comirnaty in Europe.

Pfizer/BioNTech to Supply 1.8B More Doses of Comirnaty in EU

CEO Uğur Şahin said the vaccine's effectiveness against the Indian variant was likely to be in the same 75% range as for the South African variant.

BioNTech Says Covid-19 Vaccine Likely to Be Effective Against Indian Virus Variant

BioNTech's chief executive has said that the COVID-19 vaccine it developed with U.S. pharmaceutical group Pfizer is likely to be effective against the Indian variant of coronavirus. The German biotechnology company's CEO, Ugur Sahin, said on Thursday in a meeting with the Turkish health minister that the vaccine's effectiveness against the Indian variant was likely to be in the same range as for the South African variant, according to BioNTech.

BioNTech says COVID-19 vaccine likely to be effective against Indian coronavirus variant

MAINZ, Germany, May 21, 2021 –  BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”), a next generation immunotherapy company pioneering novel therapies for cancer and infectious diseases, has published its first Sustainability Report . The report focuses on the Company's commitment to making an impact on good health and well-being, anchoring responsibility in its core business, ensuring BioNTech's resilience through responsible governance, creating values and shaping a sustainable corporate culture for growth. BioNTech was awarded a "Prime" rating in its first ESG rating by the rating agency ISS ESG. BioNTech is now ranked by ISS ESG in the top 10% of all rated companies in the Pharmaceuticals and Biotechnology sector.

BioNTech Publishes First Sustainability Report and Receives “Prime” Rating by ISS ESG

The European Commission has signed a third contract with BioNTech SE (NASDAQ: BNTX) and Pfizer Inc (NYSE: PFE) for an additional 1.8 billion doses of its COVID-19 vaccine, Comirnaty. The contract reserves the doses on behalf of all European Union member states, between the end of 2021 to 2023, the statement added.

European Commission Inks Third Supply Pact With BioNTech-Pfizer For 1.8B Vaccine Doses

Pfizer Inc. and German partner BioNTech SE said Thursday they have reached a new agreement with the European Commission to supply up to 1.8 billion additional doses of their COVID-19 vaccine. The partners said the agreement is to provide 900 million doses initially with an option for the EC to request up an additional 900 million doses.

Pfizer and BioNTech to supply EU with up to 1.8 billion additional COVID vaccine doses

ISTANBUL, TURKEY and MAINZ, GERMANY, May 20, 2021 (GLOBE NEWSWIRE) — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the BioNTech Europe GmbH has entered into an agreement with Turkey's Ministry of Health to supply 60 million additional doses of the companies' COVID-19 vaccine, with an option for an additional 30 million doses. On December 25, 2020, the two companies announced an initial agreement to provide 30 million doses of the Pfizer-BioNTech vaccine to Turkey. This second supply agreement brings the total number of doses to be supplied to Turkey to up to 120 million, all of which will be delivered in 2021.

Pfizer and BioNTech Sign Agreement for Additional Supply to Turkey of 60 Million Doses of their COVID-19 Vaccine

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced a new agreement with the European Commission (EC) to supply 900 million doses of COMIRNATY®, the companies' COVID-19 vaccine, to the European Union (EU), with an option for the EC to request up to an additional 900 million doses. This new agreement is in addition to the 600 million doses that have already been committed to the EU through 2021. The additional 900 million agreed dose

Pfizer and BioNTech to Supply the European Union With up to 1.8 Billion Additional Doses of COMIRNATY®

BioNTech (BNTX) is riding high on the robust performance of its COVID-19 vaccine, BNT162b2, which has been developed in partnership with Pfizer.

BioNTech (BNTX) Up More Than 100% So Far This Year: Here's Why

Pfizer Inc (NYSE: PFE) will begin producing an essential ingredient for its COVID-19 vaccine developed in partnership with BioNTech SE (NASDAQ: BNTX) at a facility in Ireland. An existing Pfizer facility in Grange Castle, Dublin, will be adapted to produce the "mRNA drug substance," a core component in the vaccine, for $40 million, the Irish Times reported.

Pfizer To Start Making COVID-19 Vaccine Component In Ireland By 2021 End

International Game Technology

Find 'Strong Buy' Stocks Near Highs Amid Volatility

Johnson & Johnson

Moderna

Vaccine makers, including Pfizer, Johnson & Johnson, AstraZeneca, and BioNTech, are set to make billions for many years to come.

Vaccine Makers Will Make Billions For Years To Come: Which One To Buy Now

Exelixis

Foot Locker

With the trading day about halfway over, the markets were somewhat mixed on Tuesday.

BioNTech, Exelixis, Foot Locker and More Tuesday Afternoon Analyst Calls

Entera Bio Ltd

Ocugen, Inc.

Rubius Therapeutics Inc

Stocks of BioNTech (BNTX), Ocugen (OCGN), Rubius Therapeutics (RUBY) and Entera Bio (ENTX) are up more than 100% this year so far.

4 Biotech Stocks That Have Already Doubled This Year So Far

BioNTech SE , the German biotech that partnered with Pfizer Inc. to develop a COVID-19 vaccine that is authorized for use in the U.S., said Tuesday it has named Jens Holstein as chief financial officer. Holstein will replace Dr. Sierk Poetting, who will focus on his role as chief operating officer.

BioNTech names Jens Holstein CFO

MAINZ, Germany, May 18, 2021 —  BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”), announced today that the Supervisory Board has appointed Jens Holstein to the Management Board as Chief Financial Officer (CFO). As of July 1, 2021, Jens Holstein will join the Management Board to help strengthen BioNTech on its growth trajectory as a global, fully integrated immunotherapy company with an approved or authorized product. He previously served as CFO for MorphoSys AG and in various CFO and general management roles within the Fresenius SE Group. Jens Holstein takes over the CFO role from Dr. Sierk Poetting who will fully focus on his tasks as Chief Operating Officer (COO) going forward.

BioNTech Broadens Management Board by Appointing Jens Holstein as CFO

Those plans come after the White House said it would send 60 million doses of AstraZeneca's Covid vaccine to countries in need

Biden to say U.S. will send 20 million Pfizer, Moderna or J&J vaccine doses abroad by end of June

Connect Biopharma Holdings

Fulgent Genetics

GlaxoSmithKline

Knnate Biopharma

Karyopharm Therapeutics

Legend Biotech

aTyr Pharma

Eli Lilly

Genscript raised more than $1 billion from Hillhouse Capital in several different investments, including a $500 million commitment to Genscript's Legend Biotech CAR-T subsidiary. Shanghai Fosun Pharma formed a JV with its COVID-19 partner BioNTech to manufacture their partnered mRNA vaccine in China.

Week In Review: Genscript And Its Legend Bio Subsidiary Raise $1 Billion From Hillhouse

There are several variables that will make a key difference.

How Big Is Pfizer's Vaccine Opportunity in India?

Full FDA approval might not move the stock much, but it's still very important.

News for BioNTech SE Stock (BNTX)